Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

Purpose Neuroendocrine tumours (NET) are uncommon and may be localized in many
different places in the body. Traditional imaging has mainly been performed with CT and …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …

Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …

Background Somatostatin analog functional imaging with gallium‐68 (Ga‐68) dotatate
positron emission tomography/computed tomography (PET/CT) has demonstrated …

Neuroendocrine tumors (NETs) are rare neoplasms characterized by overexpression of
somatostatin receptors (SSTRs). Functional imaging plays a crucial role in management of …

Patients with neuroendocrine tumors (NETs) are often treated with somatostatin analogs
(SSAs) for control of symptoms and tumor growth. Such therapy could theoretically lead to …

Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We
herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled …